医学
肺癌
入射(几何)
内科学
肿瘤科
血液检验
回顾性队列研究
癌症
考试(生物学)
肺
癌症发病率
药品
血癌
梅德林
生物信息学
病理
血液检测
出处
期刊:Cancer Discovery
[American Association for Cancer Research]
日期:2026-06-16
卷期号:: OF1-OF1
标识
DOI:10.1158/2159-8290.cd-nw2026-0070
摘要
A 14-protein blood test can identify people at high risk of lung cancer more than 5 years before a tumor becomes detectable on imaging, including never-smokers who fall outside current screening criteria. In a retrospective analysis, the test also identified individuals most likely to benefit from the anti-IL-1β drug canakinumab, which roughly halved lung cancer incidence in the high-risk group but not in low-risk participants.
科研通智能强力驱动
Strongly Powered by AbleSci AI